Clinical Trials Using F-18 16 Alpha-Fluoroestradiol
Clinical trials are research studies that involve people. The clinical trials on this list are studying F-18 16 Alpha-Fluoroestradiol. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
FES PET / CT in Predicting Response in Patients with Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET) / computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body. FES is a radioactive form of the hormone estrogen and may “light up” where cancer is in the body. Diagnostic procedures using FES, such as FES PET / CT, may help measure the FES and help doctors predict how well the cancer will respond to treatment.
Location: 18 locations
PET / MRI Breast Imaging in Assessing Estrogen Receptor Status in Patients with Ductal Breast Carcinoma In Situ
This phase II trial compares a new imaging method for measuring estrogen receptor level (expression) in breast cancer with the standard method of measuring estrogen receptor expression by staining cancer tissue obtained from biopsy or surgery. This new method is using combined positron emission tomography / magnetic resonance imaging (PET / MRI) scans. Studying how well PET / MRI works in assessing estrogen receptor expression may help doctors to develop and implement PET / MRI for diagnosing, staging, and monitoring treatment response in patients diagnosed with estrogen receptor positive breast cancer.
Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
F-18 16 Alpha- Fluoroestradiol PET / CT Scan in Evaluating Endocrine Therapy Response in Participants with Newly Diagnosed, Estrogen Receptor Positive Metastatic Breast Cancer
This phase II trial studies how well F-18 16 alpha-fluoroestradiol positron emission tomography (PET) / computed tomography (CT) scan works in evaluating endocrine therapy response in participants with newly diagnosed, estrogen receptor positive breast cancer that has spread to other places in the body. Imaging drugs, F-18 16 alpha-fluoroestradiol, may help evaluate breast cancer and predict how well cancer responds to therapy. Using F-18 16 alpha-fluoroestradiol with PET / CT my help doctors better improve and plan better treatment options.
Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas
FES-PET / CT in Predicting Treatment Response in Patients with Endocrine Refractory, Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer
This research trial studies F-18 16 alpha-fluoroestradiol (FES)-positron emission tomography (PET) / computed tomography (CT) in predicting response to treatment in patients with estrogen receptor-positive breast cancer that that does not respond to endocrine treatment (endocrine refractory) and has come back (recurrent) or has spread to other parts of the body (metastatic). FES-PET / CT is a type of scan that measures the amount of estrogen receptors in the breast cancer, which may be a sign of how the cancer is responding to treatment. If the levels of estrogen receptors can predict the cancer's response to treatment, and can be measured using FES-PET / CT scans, doctors may be able to choose a treatment that works best for each patient and measure how well the patient is responding without performing surgery for a biopsy.
Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania
Fluoroestradiol PET / CT Imaging in Detecting Tumor Changes in Patients with Estrogen Receptor Positive Cancer
This clinical trial studies how well F-18 16 alpha-fluoroestradiol positron emission tomography / computed tomography (PET / CT) imaging works in detecting tumor changes in patients with estrogen receptor positive cancer. Diagnostic drugs, such as F-18 16 alpha-fluoroestradiol, may be absorbed by tumor cells with estrogen receptors and bind to them. PET / CT imaging can find how much F-18 16 alpha-fluoroestradiol present. F-18 16 alpha-fluoroestradiol PET / CT imaging may help monitor changes in estrogen receptors in tumors during treatment.
Location: Memorial Sloan Kettering Cancer Center, New York, New York